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Supplementary Fig. 1. Schematic Work Flowchart of Human Samples analyses. We did two 
global unbiased analyses (RNA sequencing and DNA Methylation chip) and two focused studies 
(Liver ChIP-seq and GWAS). For details in cohorts analyzed and the type of analysis performed 
in this study see Materials and Methods section. 
  
 
 
Supplementary Fig. 2. Time-dependent patterns of gene expression in ALD patients. Linear 
plot of normalized counts for each profile of genes derived from Short Time Expression Mining 
(STEM) algorithm along different phenotypes reflecting disease progression. (a) STEM profiles 9, 
23, 0 and 12, showing patterns of continuous downregulation, (b) STEM profiles 29, 42, 49 and 
48, showing patterns of continuous upregulation (c) STEM profiles 34 and 31, showing patterns 
of upregulation in early ASH patients and downregulation in AH patients. (d) STEM profiles 18, 7 
and 21, showing downregulation in early ASH patients and upregulation in AH patients. P-values 
of profile enrichment are presented.. N: Normal Liver, E: Early Alcoholic Steato-hepatitis (ASH), 
AH: Alcoholic Hepatitis, exAH: explants from patients transplanted for AH.  
  
  
 
 
Supplementary Fig. 3. Transcriptome changes in ALD reflect hepatocellular 
disfunction. Results of Gene Set Expression Analysis (GSEA) performed by computing gene set 
overlaps of the 2000 genes most positively and negatively correlated with disease progression 
from normal livers to explants from livers with AH (exAH). Top 10 most enriched gene sets are 
shown.  
  
 
 
Supplementary Fig. 4. Mouse model of acute-on-chronic alcohol mediated liver injury 
partially reproduces features of human AH transcription factor reprogramming. (a) Five 
experimental models were used in order to reproduce different stages and grades of alcohol-
related liver injury in C57BL/6J mice. Liver RNA was extracted and sequenced (n = 4 per each 
group): Group 1: Olive oil for 6 weeks (“Control”); Group 2: High dose CCl4 (0.2 ml/kg) for 6 
weeks (”CCl4 6W”). Group 3: Olive oil for 6 weeks + surgery (intra-gastric canulae) and 1 week 
post-op recovery + Ethanol for 3 more weeks (“EtOH”); Group 4: High dose CCl4 for 6 weeks + 
surgery (intra-gastric canulae) and 1 week post-op recovery + low dose CCl4 (0.1 ml/kg) for 3 
more weeks (“CCl4 9W”); Group 5: High dose CCl4 for 6 weeks + surgery (intra-gastric canulae) 
and 1 week post-op recovery + Ethanol and low dose CCl4 for 3 more weeks (“CCl4 9W+EtOH”) 
(b-e) Biochemical and histological analysis of liver injury (b) Steatosis assessment: quantitative 
analysis of Oil RedO staining (5 random fields at 200× magnification) and triglyceride levels in 
liver tissue. (c) Inflammation and fibrosis assessment: Serum alanine aminotransferase levels 
and quantitative analysis of MPO-positive cell counts and Sirius red staining (5 random fields at 
200× magnification). A composite Liver Injury Score was calculated. (d) Images of Hematoxylin-
Eosin, Oil Red-O and Sirius red staining. Magnification 100–200X, scale bar = 200 μm. (e) Higher-
resolution images of Sirius red. Magnification 400×, scale bar = 50 μm (f) Transcription factor 
analysis performed by the overlapping of Ingenuity Pathway Analysis predicted activation (PPA) 
and Opossum analysis of transcription factor binding motif enrichment analysis (MEA) in gene 
promoters (+/- 2kb from TSS). Arrows indicate those TF which were also found in AH patients 
either in early phases or in late phases of disease progression (cfr. Fig. 2c,d), and are colored in 
green when changes are consistent and in red if they are not-consistent with human data. (g) 
qPCR of liver RNA from same animals (n=3); qPCR of HNF4a-P1 and P2 isoforms and of HNF4a 
targets PCK1 and F7. Significance was determined by two-tailed Mann–Whitney U test in b, c 
and g and is denoted as follows: a = p < 0.05, compared with control group; b = p < 0.05, compared 
with CCl4(6w) group; c = p < 0.05, compared with CCl4(9w) group; d = p < 0.05, compared with 
EtOH group. For box-and-whisker plots: perimeters, 25th–75th percentile; midline, median; 
whiskers, minimum to maximum values; individual data points are represented.  The significance 
of DE analyses was considered when multiple testing-corrected p-value < 0.01. 
  
 Supplementary Fig. 5. RNA-seq analysis reveals HNF4A splicing dysregulation in patients 
with AH. (a) Scheme of exon relative size along HNF4a transcript. (b) Analysis of HNF4A exon-
specific expression using TrimGalore trimming, STAR alignment and DEXSeq package. False 
Discovery Ratio (FDR) was calculated. (c-e) Pearson correlation analysis of exon 1D and each 
of the other HNF4A exons in (c) Normal or (d) AH livers. (e) Holm method was used to calculate 
adjusted p-values and Pearson’s R for each correlation in (c) and (d). Green boxes (left column) 
indicate significant correlation (P<0.05). Red-Orange-Yellow boxes (right column) were used to 
illustrate R values. (f) Replicate multivariate analysis of transcript splicing (rMATS) pipeline was 
adopted to uncover new isoforms from exon exclusion splicing events. (left) Scheme of the 
splicing junctions resulting in significant exon-exclusion events in Normal and AH livers. Excluded 
exons and possible splicing reactions are depicted as colored (orange/blue) boxes and black lines 
respectively. (Center) Exon sequence resulted from exon exclusion. (right) Quantification of exon-
exclusion events in Normal and AH livers. FDR was calculated to detect significant differences 
on Exon Exclusion ratio comparing normal vs AH livers.  
 
  
  
Supplementary Fig. 6. Immunohistochemistry of HNF1a and FOXA1 show decreased 
nuclear signal and cytoplasmic staining in AH patients. (a) Representative images of HNF1a 
and FOXA1 Immunohistochemistry (IHC) in normal and AH livers. (b,c) Semi-quantitative scoring 
of signal intensity in the nuclei and the cytoplasm (0, low intensity/absence of signal; 1, medium 
intensity; 2, high intensity; 3 very high intensity) of hepatocytes for (b) HNF1a and (c) FOXA1 
IHCs. (d) RXRa IHC in normal and AH livers. (e) Semi-quantitative scoring of RXRa signal 
intensity in the nuclei and the cytoplasm (0, low intensity/absence of signal; 1, medium intensity; 
2, high intensity; 3, very high intensity). Significance of semiquantitative scoring was determined 
by Fisher exact probability test. *P <0.05 
  
 
 
Supplementary Fig. 7. Markers of hepatocyte de-differentiation and epithelial-to-
mesenchymal transition (EMT) are increased in AH patients. (a) (Left-center) Heatmap 
showing normalized RNA-seq counts of genes related to EMT. (Right) Kendall correlation index 
and significance (expressed as -log of Fold Discovery Ratio (FDR) for the progression from 
normal to early ASH, AH and exAH. (Right) Relative transcript levels (“Signal”) of each gene. (b,c) 
Results from Correlation Engine (Illumina BaseSpace) analysis of progression from normal to AH 
explants by correlation with specific tissue (b) and cell type (c) datasets. The score indicates the 
magnitude of the correlation, and the color indicates if there is a direct correlation with upregulated 
genes (red) or with downregulated genes (blue). Only the first hit of each organ/cell type is 
presented.  
  
  
 
Supplementary Fig. 8. Silencing of HNF4a-P2 enhances Glyco conjugation of cheno-
deoxycolic acid in primary human hepatocytes.  Primary Human Hepatocytes were 
transfected with HNF4a-P2 specific siRNA. Supernatant was collected at base line, 8h, 24h and 
48h. The levels of glycochenodeoxycholate were measured by mass spectrometry. Data is 
presented as mean and standard error of the mean. Significance was determined by two-tailed 
Mann–Whitney U test *P < 0.05. 
  
 
 
Supplementary Fig. 9. Mechanism of TGFb1 and AREG-mediated HNF4a downregulation. 
(a,b) Hep3B cells were serum-starved overnight before treatment with TGFb1 (5 ng/ml) and/or 
AREG (50 nM) for the indicated time points (n = 3 for each condition). (a) qPCR of HNF4a-P1 (b) 
qPCR of HNF4a-P2 (c) Hep3B cells were pretreated with the EGFR inhibitor PD153035 (PD15, 
25 μM) for 12h and then treated with AREG (50 nM) for additional 12h (n = 2 for each condition).  
Immunoblot of HNF4a-P1. (d) Hep3B cells were serum starved and pretreated overnight with 
MEK/ERK inhibitor UO126 (10 µM) and then treated with AREG (50 nM) for additional 12h (n = 2 
for each condition). Immunoblot of HNF4a-P1. (e,f) Hep3B cells were serum starved and 
pretreated overnight with c-Src inhibitor PP2 (10 µM) and then treated with (e) AREG or (f) EGF 
(50 nM) for additional 12h (n = 2 for each condition). Immunoblot of HNF4a-P1. (g) Hep3B cells 
treated with AREG (50 nM) for 24h with the addition of proteasome inhibitor MG132 (10 µM) 2h 
before collection when indicated (n = 2 for each condition). Immunoblot of HNF4a. (h,i) Hep3B 
cells were serum starved and pretreated overnight with MEK/ERK inhibitor UO126 (10 µM) and 
then treated with TGFb1 (5 ng/ml) for additional 12h (n = 2 for each condition); (h) qPCR of 
HNF4a-P1 and P2; (i) Immunoblot of HNF4a-P1 and P2. Significance was determined by two-
tailed Mann–Whitney U test in a and b: *P < 0.05, **P<0.01. For box-and-whisker plots in a and 
b: perimeters, 25th–75th percentile; midline, median; whiskers, minimum to maximum values; 
individual data points are represented. Gene expression is presented as relative values 
normalized to the mean of the control. 
  
 
 
 
 
Supplementary Fig. 10. c-JUN sites in HNF4a-P2 promoter region (TSS+/-1kb) (a) Output of 
JASPAR2018 Basic Sequence Analysis tool, using the matrix profiles “FOS::JUN” heterodimer 
(MA0099.2 and MA0099.3) and “JUN” (MA0488.1) (b) schematic presentation of HNF4a-P2 
promoter region (TSS+/-1kb) with indicated the FOS::JUN sites (red squares) and the primers 
used for the qPCR. 
  
 
 
Supplementary Fig. 11. Plasma liver-secreted LETF-dependent protein levels correlate 
with liver transcript changes. Plasma from healthy controls (N=10) and from patients with AH 
(N=15) was pooled, depleted from top 12 most abundant proteins, digested and analyzed by liquid 
chromatography coupled to mass spectrometry (LC-MS/MS). (a) Venn diagram showing the 
number of common proteins detected in plasma of healthy (334 proteins) and AH (431 proteins). 
(b) Filtering of RNA-seq differential expressed genes (DEG) between Normal and AH livers, by 
the presence of signal peptide (278 proteins) and the absence of transmembrane domain to 
obtain a list of DE secreted protein coding genes (244 proteins). (c) Venn diagram of liver DE 
secreted protein coding genes and plasma protein detected by LC-MS/MS (d) Chart illustrating 
target genes of TFs predicted to inhibited in AH patients (cfr. Fig 1g) and their fold change (FC) 
in RNA-seq and LC-MS/MS experiments. Colors indicate relative intensity of FC in both analyses 
either down (blue scale) or upregulated (red scale). (e)  Correlation plot of FC of genes in d in 
RNA-seq and LC-MS/MS experiments, indicating R2 spearman correlation index. 
  
  
Supplementary Fig. 12. Complementary approach for identifying transcription factors that 
regulate liver transcriptome. (a) Scheme of unbiased complementary approach used to 
generate Fig. 1g,h and Fig. 3p by overlapping outputs from transcription factor binding motif 
searching engine (Opossum) and pathway enrichment software (Ingenuity Pathway Analysis) 
with the conditions used. (b) Venn diagram showing the overlap of Normal vs Early ASH livers or 
(c) Early ASH vs AH livers. 
  
 
 
Supplementary Table 1. Baseline characteristics of patients and controls at the time of liver biopsy. 
 
 
WBC: White blood count; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; GGT: Gamma Glutamyl Transpeptidase; ALP: Alkaline Phosphatase; INR: International 
Normalized Ratio. N/A: Do not apply; N/D: Undetermined (Missing data) 
 Early ASH 
n=12 
Severe AH 
n=18 
Severe AH 
(explants) 
n=11 
Normal livers 
n=10 
NASH 
n=9 
HCV 
n=10 
Comp. Cirrhosis 
n=9 
Demographics         
Age - median (IQR) 52(48.2-58.7) 51(47.2-57.7) 48.9(48-56) 32(28.8-50.7) 49.5(43-53) 46(43-62.5) 61(51.3-66) 
Gender - male n (%) 7(58.3) 11(61.1) 7(63.6) 7(70) 2(25) 5(50) 7(77.7) 
Severity scores – median (IQR)        
Child-Pugh N/A 11(9-11.7) 10.7(9-12) N/A N/A N/A 5(5-5) 
MELD N/A 24(22-27.7) 24.5(21.4-27.2) N/A N/A N/A 10(8.5-12) 
ABIC N/A 8.3(7.8-8.8) N/D N/A N/A N/A N/D 
Decompensations - N(%)       
Ascites 0 14(83.3) 7(72.7) 0 0 0 0 
Hepatic Encephalopathy 0 5(27.8) 1(9) 0 0 0 0 
Upper GI Bleeding 0 1(5.6) 2(18.2) 0 0 0 0 
Acute Kidney Injury 0 10 (55.6) N/D 0 0 0 0 
Infections 0 5(33.3) 5(55.6) 0 0 0 0 
Lab parameters - median (IQR)        
Hemoglobin g/dL  14.3(13.6-16.6) 11.6 (10.7-13.2) N/D 14.6(12.9-15.5) 14.3(12.5-14.9) 14.8(14.2-16.5) 16.1(13.6-17.1) 
WBC x109/L 5.6(4.6-7.2) 8.3 (6.6-12.7) 10.8(7.4-14.2) 5.7(5.1-7.2) 8.1(6.9-10.2) 6.4(5.9-6.8) 5.5(4.4-6.9) 
Platelets x109/L 179(121-237) 118 (67-208) N/D 237(210-282) 262(221-361) 214(174-247) 142(119-176) 
AST (U/L) 107(64-154) 114.5 (62.5-158.3) 170(131-279) 21.5(18.8-26.5) 30(25-36.3) 54(41.3-63.5) 86(63-107) 
ALT (U/L) 70.3(53.5-89.8) 32.5 (20-44) N/D 25(14.8-34.3) 40(31-49.5) 85(59.8-113) 113(77.5-155) 
Bilirubin mg/dL 1.2(0.7-1.5) 19 (12.3-26.7) 16.3(11.1-24.3) 0.6(0.5-0.7) 0.6(0.4-0-9) 0.75(0.6-1) 1.1(0.78-1.65) 
GGT (U/L) 388(200-723) 406(165-721) N/D 17(13.5-24.8) 27(10-31) 36.5(24.3-48.3) 45(32.7-186) 
ALP (U/L) 100(62-141) 386(147-491) N/D 147(106-191) 182(170-195) 162(134-200) 176(145-301) 
Albumin (g/dL) 4.5(4.2-4.7) 2.9 (2.3-3.3) 2.4(2-3) 4.6(4.3-4.6) 4.5(4.4-4.6) 4.4(4.2-4.7) 4.1(40.3-45) 
Creatinine mg/dL 0.6(0.59-0.77) 0.79 (0.61-1) 0.69(0.53-0.73) 0.8(0.74-0.9) 1.05(0.84-1.1) 1(0.98-1.1) 1(0.83-1.1) 
Sodium (mEq/L) 139(136-140) 136(132-139) N/D 140(138.7-141.5) 140(136-142.5) 142.5(140-143.3) 141(139-143) 
INR 1(0.9-1) 1.6 (1.2-3.3) 1.8(1.6-2.6) 1.03(0.99-1.06) 1.19(1.06-1.35) 1.21(1.01-1.40) 1.24(1.16-1.38) 
Supplementary Table 2. Oligonucleotide sequences of primers used for Real Time PCR. 
 
Gene Symbol Gene Name Forward Primer (5’-3’) Reverse Primer (5’-3’) 
HNF4A -P1 Homo sapiens hepatocyte nuclear factor 4 alpha (HNF4A), P1 dependent isoforms (a1-6) AGAATGTGCAGGTGTTGACG CTCGAGGCACCGTAGTGTTT 
HNF4A -P2 Homo sapiens hepatocyte nuclear factor 4 alpha (HNF4A), P1 dependent isoforms (a7-9) GGCCATGGTCAGCGTGAACG GCCCTTGCAGCCGTCACAGC 
HNF4A-AS1 Homo sapiens HNF4A antisense RNA 1 CCTTGTTGGGGAAGCAAGTA ACTCAGGCTGGAGTGCAGTT 
PCK1 Homo sapiens Phosphoenolpyruvatecarboxykinase 1 GATGTGGCCAGGATCGAAAGCAAGAC ATGATCCGCATGCTGGCCACCAC 
ALB Homo sapiens Albumin TATGCCCCGGAACTCCTTTT TGGCACACTTGAGTCTCTGT 
OTC Homo sapiens ornithine carbamoyltransferase TTGCACTTCTGGGAGGACAT TAGTGTTCCTGGAGCGTGAG 
F7 Homo sapiens coagulation factor VII CGATGCTGACTCCATGTGTG GGAAGCAGGTGGGGAATAGT 
BSEP 
(ABCB11) Homo sapiens ATP binding cassette subfamily B member 11 CAGTGGAAAGAGGGACCCAT TCTGCTAAAGGTCCTCGCAA 
CYP2E1 Homo sapiens cytochrome P450 family 2 subfamily E member 1 GCAACCCGAGACACCATTTT GCACACACTCGTTTTCCTGT 
CYP7A1 Homo sapiens cytochrome P450 family 7 subfamily A member 1 CACCTTGAGGACGGTTCCTA CGATCCAAAGGGCATGTAGT 
CYP27A1 Homo sapiens cytochrome P450 family 27 subfamily A member 1 AGCTGCGCTTCTTCTTTCAG GCTCCATGTCGTTCCGTACT 
KRT7 Homo sapiens keratin 7 CAGGATGTGGTGGAGGACTT AGCTCTGTCAACTCCGTCTC 
EPCAM Homo sapiens epithelial cell adhesion molecule CAGAAGGAGATCACAACGCG TCCAGATCCAGTTGTTCCCC 
VIM Homo sapiens Vimentin GAGTCCACTGAGTACCGGAG ACGAGCCATTTCCTCCTTCA 
RPL4 Ribosomal Protein L4 GCTCTGGCCAGGGTGCTTTTG ATGGCGTATCGTTTTTGGGTTGT 
SMAD4 SMAD family member 4 GCTGCTGGAATTGGTGTTGATG AGGTGTTTCTTTGATGCTCTGTCT 
HNF4A Prom TSS-809-P2 GTGTGTGAGTTTCAGCAGCA TGAGGGGTGGAGAAACATGG 
HNF4A  Prom TSS+338-P2 CTTGGTGCGAGAAGTGCTG AGACCCCTGAGATGCATTCC 
GAPDH prom unknown TACTAGCGGTTTTACGGGCG TCGAACAGGAGGAGCAGAGAGCGA 
 
 
 
Supplementary Table 3. Antibodies used for Western Blot 
 
Protein Supplier (#Cat) Application Working Dilution 
HNF4a1-6 (P1 dependent 
isoforms) R&D (PP-K9218-00) Western Blot 1:1000 
HNF4a7-9 (P2 dependent 
isoforms) R&D (PP-H6939-00) Western Blot 1:1000 
b-ACTIN Sigma-Aldrich (A5441) Western Blot 1:1000 
Phopho-c-JUN (T91/93/95) Life (711207) ChIP 5 ug/ml 
RNA Polymerase II Sigma-Aldrich (05-623B)  ChIP 1 ug/ml 
Normal Mouse IgG Sigma-Aldrich (12-371B) ChIP 1 ug/ml 
 
 
 
Supplementary Table 4. Antibodies and conditions for Immunohistochemistry 
 
 
Antigen 
Antigen retrieval 
Incubation time 
Buffer 
Blocking 
Incubation time 
Primary antibody 
Company 
Dilution, incubation time 
Detection System 
Company Chromogen 
HNF4a 1-6 (P1) Microwave, TE pH 6.0, 40’ REAL™ (Dako), 10’ 
Clone K9218 (Perseus), 
1:100, 60‘ 
IDetectTM Super Stain System–HRP 
(Empire) AEC 
HNF4a 7-9 (P2) Microwave, TE pH 6.0, 40’ REAL™ (Dako), 10’ 
Clone H6939 (Perseus), 
1:100, 60’ Envision (Dako) DAB 
HNF1a Microwave, TE pH 9.0, 40’ REAL™ (Dako), 10’  
ab204306 (Abcam), 
1:200, 60’ 
IDetectTM Super Stain System–HRP 
(Empire) AEC 
FOXA1 Microwave, TE pH 9.0, 40’ REAL™ (Dako), 10’ 
Clone #654126 (R&D), 
1:100, 60’ 
IDetectTM Super Stain System–HRP 
(Empire) AEC 
RXRa CC, 60’ REAL™ (Dako), 10’ Clone K8508 (R&D), 1:100, 32‘  Ultraview (Ventana) DAB 
 
